HK1039751A1 - 3-(1h-咪唑-4-基甲基)-二氫化茚-5-醇在製備用於脊柱內、鞘內或硬膜外給藥的藥物中的應用 - Google Patents

3-(1h-咪唑-4-基甲基)-二氫化茚-5-醇在製備用於脊柱內、鞘內或硬膜外給藥的藥物中的應用

Info

Publication number
HK1039751A1
HK1039751A1 HK02101329.8A HK02101329A HK1039751A1 HK 1039751 A1 HK1039751 A1 HK 1039751A1 HK 02101329 A HK02101329 A HK 02101329A HK 1039751 A1 HK1039751 A1 HK 1039751A1
Authority
HK
Hong Kong
Prior art keywords
indan
imidazol
ylmethyl
manfacture
intraspinal
Prior art date
Application number
HK02101329.8A
Other languages
English (en)
Inventor
A‧哈帕林納
J‧萊提馬基
T‧萊諾
T‧維特馬
R‧沃坦恩
Original Assignee
歐裏恩公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 歐裏恩公司 filed Critical 歐裏恩公司
Publication of HK1039751A1 publication Critical patent/HK1039751A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK02101329.8A 1998-09-28 2002-02-22 3-(1h-咪唑-4-基甲基)-二氫化茚-5-醇在製備用於脊柱內、鞘內或硬膜外給藥的藥物中的應用 HK1039751A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10198698P 1998-09-28 1998-09-28
PCT/FI1999/000793 WO2000018400A1 (en) 1998-09-28 1999-09-27 Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration

Publications (1)

Publication Number Publication Date
HK1039751A1 true HK1039751A1 (zh) 2002-05-10

Family

ID=22287519

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02101329.8A HK1039751A1 (zh) 1998-09-28 2002-02-22 3-(1h-咪唑-4-基甲基)-二氫化茚-5-醇在製備用於脊柱內、鞘內或硬膜外給藥的藥物中的應用

Country Status (24)

Country Link
US (1) US6495584B1 (zh)
EP (1) EP1117399B1 (zh)
JP (1) JP4647785B2 (zh)
KR (1) KR100646811B1 (zh)
CN (1) CN1320034A (zh)
AT (1) ATE288753T1 (zh)
AU (1) AU756104B2 (zh)
BG (1) BG105469A (zh)
CA (1) CA2345521C (zh)
CZ (1) CZ299918B6 (zh)
DE (1) DE69923698T2 (zh)
DK (1) DK1117399T3 (zh)
EA (1) EA003216B1 (zh)
EE (1) EE200100193A (zh)
ES (1) ES2237205T3 (zh)
HK (1) HK1039751A1 (zh)
HU (1) HU227634B1 (zh)
IL (2) IL141680A0 (zh)
NO (1) NO330436B1 (zh)
NZ (1) NZ510233A (zh)
PL (1) PL346908A1 (zh)
SK (1) SK3812001A3 (zh)
UA (1) UA61152C2 (zh)
WO (1) WO2000018400A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1196168A2 (en) * 1999-06-25 2002-04-17 Orion Corporation Method of admistering an imidazole derivative to obtain analgesia
FI20022159A0 (fi) 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US5801188A (en) * 1997-01-08 1998-09-01 Medtronic Inc. Clonidine therapy enhancement

Also Published As

Publication number Publication date
CZ299918B6 (cs) 2008-12-29
CA2345521C (en) 2009-05-05
DE69923698T2 (de) 2006-01-12
DK1117399T3 (da) 2005-03-29
DE69923698D1 (de) 2005-03-17
KR20010079860A (ko) 2001-08-22
AU5986099A (en) 2000-04-17
BG105469A (en) 2001-11-30
IL141680A0 (en) 2002-03-10
HU227634B1 (en) 2011-10-28
EA200100405A1 (ru) 2001-10-22
HUP0103864A2 (hu) 2002-05-29
EP1117399B1 (en) 2005-02-09
AU756104B2 (en) 2003-01-02
SK3812001A3 (en) 2002-02-05
NO20011545D0 (no) 2001-03-26
CN1320034A (zh) 2001-10-31
NO20011545L (no) 2001-03-26
EP1117399A1 (en) 2001-07-25
IL141680A (en) 2007-06-17
KR100646811B1 (ko) 2006-11-17
EE200100193A (et) 2002-08-15
NO330436B1 (no) 2011-04-11
JP2002525324A (ja) 2002-08-13
NZ510233A (en) 2003-05-30
CZ2001933A3 (cs) 2001-08-15
CA2345521A1 (en) 2000-04-06
UA61152C2 (en) 2003-11-17
EA003216B1 (ru) 2003-02-27
PL346908A1 (en) 2002-03-11
US6495584B1 (en) 2002-12-17
JP4647785B2 (ja) 2011-03-09
HUP0103864A3 (en) 2002-08-28
WO2000018400A1 (en) 2000-04-06
ES2237205T3 (es) 2005-07-16
ATE288753T1 (de) 2005-02-15

Similar Documents

Publication Publication Date Title
Patel et al. Remifentanil
JPH06157301A (ja) トラマドール物質及び非ステロイド抗炎症薬を含んで成る組成物
EE200300106A (et) Farmatseutiline kompositsioon kui süsteemne analgeetikum
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
WO2000010551A3 (en) Methods of using and compositions comprising dopamine reuptake inhibitors
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
AU1708202A (en) Organic compounds
MX2007006637A (es) Uso de atazanavir para mejorar los parametros farmacocineticos de farmacos metabolizados por isoforma 1a1 de udp-glucuronosil- transferasa.
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
WO1994016689A1 (en) Analgesic medicinal composition
HK1039751A1 (zh) 3-(1h-咪唑-4-基甲基)-二氫化茚-5-醇在製備用於脊柱內、鞘內或硬膜外給藥的藥物中的應用
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
WO2005065372A3 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
MX2022003982A (es) Metodos de tratamiento de enfermedades relacionadas con el receptor s1p1.
MXPA04010658A (es) Tratamiento de dolor con ifenprodil.
WO2001000192A3 (en) Method of administering an imidazole derivative to obtain analgesia
Luthra et al. Intravenous Anesthetic Agents
MXPA02007454A (es) Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor.
JPS646169B2 (zh)
US20070043111A1 (en) Use of ifenprodril in the treatment of pain
RU2003106200A (ru) Способ анестезиологического пособия при оперативных вмешательствах
RU2002121654A (ru) Способ обезболивания при операциях на конечностях
RU2003102292A (ru) Способ анестезии при онкохирургических операциях на органах брюшной полости